Brenda Coulter is a seasoned business development executive with extensive experience in global regulatory affairs, lifecycle safety, medical information, and drug development solutions. Currently at IQVIA since July 2021, Brenda specializes in both consulting engagements and full FSP outsourcing. Brenda held key roles at CATO SMS (now Allucent) as Director of Business Development, where responsibilities included selling regulatory strategy services and managing clinical studies. Prior experience includes serving as Director of Business Development at Synchrogenix, where Brenda focused on regulatory consulting and proprietary software sales, and as Vice President of Business Development at DataVersant, overseeing data governance solutions. Brenda's career also includes significant positions at PAREXEL, where responsibilities spanned from account management to proposal writing across diverse therapeutic areas. Brenda holds a BS in Business Management from the University of Phoenix.